Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on X:
“Thank you to OncoDaily for the invitation to submit this manuscript following Tandem 2026.
Cellular immunotherapy is moving quickly – not just in response rates, but in engineering sophistication, toxicity understanding, and global scalability.
In this piece, I reflect on:
- Advances in next-generation receptor design
- The growing promise (and complexity) of allogeneic and iPSC-derived platforms
- Histology-specific toxicity biology
- Real-world challenges of durability, manufacturing, and access
It’s an exciting and pivotal moment for the field – where innovation must align with practicality to truly expand patient impact.
If you’re interested in where cellular therapy may be heading next, take a read.
Thank you again to the OncoDaily team for fostering thoughtful global oncology dialogue.”
Other OncoDaily articles featuring Yan Leyfman.